Holen Sie sich die Stockscreener-App
7.44
3.12%
-0.24
Handel nachbörslich:
7.49
0.05
+0.67%
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Up 0.3% – Here’s What Happened - Defense World
(EPRX.WT.A) Advanced Equity Analysis - Stock Traders Daily
(EPRX) Technical Data (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Stock Trading Blueprint - Stock Traders Daily
(EPRX) Comprehensive Trading Strategy Report (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Daily Stock Insights - Stock Traders Daily
Uncover the Best-Performing Canadian Biotech Stocks of 2025 - Investing News Network
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December - MarketBeat
Trading (EPRX) With Integrated Risk Controls (EPRX:CA) - Stock Traders Daily
How the (EPRX.WT.A) price action is used to our Advantage - Stock Traders Daily
(EPRX) Equity Market Report (EPRX:CA) - Stock Traders Daily
562,500 Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Can Eupraxia Pharmaceuticals Inc. stock sustain institutional interest2025 Major Catalysts & Low Drawdown Trading Techniques - Улправда
Will Eupraxia Pharmaceuticals Inc. stock reach Wall Street targetsEntry Point & Community Verified Swing Trade Signals - Улправда
(EPRX) Advanced Trading Insights (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Why Eupraxia Pharmaceuticals Inc. stock is a must watch in 2025Quarterly Trade Report & Long-Term Safe Return Strategies - Улправда
Moving Averages: Why Eupraxia Pharmaceuticals Inc. stock is a must watch in 2025July 2025 News Drivers & Momentum Based Trading Ideas - Улправда
Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolutionTrade Signal Summary & Short-Term High Return Ideas - Улправда
Can Eupraxia Pharmaceuticals Inc. stock beat analyst upgradesMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Stock Report: Will Eupraxia Pharmaceuticals Inc. stock deliver better than expected guidanceJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Why Eupraxia Pharmaceuticals Inc. stock could see breakout soonDay Trade & Risk Controlled Stock Pick Alerts - Улправда
Aug Decliners: Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolution2025 Historical Comparison & Daily Chart Pattern Signals - Улправда
Aug Final Week: How Eupraxia Pharmaceuticals Inc. stock valuations compare to rivalsTrend Reversal & High Accuracy Investment Entry Signals - Улправда
What insider trading reveals about Eupraxia Pharmaceuticals Inc. stock - DonanımHaber
How Eupraxia Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Macro Moves & AI Driven Price Predictions - DonanımHaber
How geopolitical risks impact Eupraxia Pharmaceuticals Inc. (X43) stockWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
Market Review: Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolutionTrade Entry Summary & Growth Oriented Trade Recommendations - Улправда
(EPRX.WT.A) Stock Evaluation Report - Stock Traders Daily
Why Eupraxia Pharmaceuticals Inc. stock remains a top recommendationProduct Launch & Intraday High Probability Alerts - DonanımHaber
Will Eupraxia Pharmaceuticals Inc. stock deliver better than expected guidance2025 Risk Factors & Daily Market Momentum Tracking - Улправда
Bearish Setup: Why Eupraxia Pharmaceuticals Inc. stock could see breakout soon2025 Institutional Moves & Low Risk Entry Point Tips - Улправда
(EPRX.WT.A) Strategic Equity Report - Stock Traders Daily
How to Take Advantage of moves in (EPRX) (EPRX:CA) - news.stocktradersdaily.com
FY2025 Earnings Estimate for EPRX Issued By Lifesci Capital - MarketBeat
(EPRX.WT.A) Risk-Controlled Trading Report - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.3% – Here’s Why - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Strong-Buy at Lifesci Capital - Defense World
New Highs: How Eupraxia Pharmaceuticals Inc stock reacts to global recession fears2025 Historical Comparison & Fast Moving Trade Plans - moha.gov.vn
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded to "Strong-Buy" at Lifesci Capital - MarketBeat
Eupraxia Pharmaceuticals Inc. (EPRXF) Competitors - Meyka
(EPRX.WT.A) Investment Analysis and Advice - Stock Traders Daily
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Analysts see more than 77% upside for Eupraxia Pharmaceuticals (EPRX), here’s why - MSN
CapEx per share of Eupraxia Pharmaceuticals Inc Warrant 2021-09.03.2026 on Eupraxia Pharma Rg – TSX:EPRX.WT - TradingView
Is Eupraxia Pharmaceuticals Inc. stock oversold or undervaluedWeekly Trade Review & Verified Technical Signals - Newser
Will Eupraxia Pharmaceuticals Inc. (X43) stock outperform global peersJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why - Finviz
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Yahoo Finance
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Return on invested capital % of Eupraxia Pharmaceuticals, Inc. – LS:A3EGRS - TradingView — Track All Markets
Net current asset value per share of Eupraxia Pharmaceuticals, Inc. – LS:A3EGRS - TradingView
Is Eupraxia Pharmaceuticals Inc. stock a bargain at current levelsWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Is Eupraxia Pharmaceuticals Inc. (X43) stock testing key supportJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser
How Eupraxia Pharmaceuticals Inc. (X43) stock correlates with oil markets2025 Institutional Moves & Weekly High Potential Alerts - Newser
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):